Abstract
Background: PRODIGE 20 randomized patients ( pts) aged 75+ to receive bevacizumab + chemotherapy (LV5FU2, FOLFOX, FOLFIRI, according investigators choice) or chemotherapy alone. The primary endpoint based on efficacy and safety was reached in BEV‐CT. This analysis presents updated progression‐free survival (PFS) and overall survival (OS), including univariate and multivariate analyses. Methods: PFS was defined as time from randomization to progression or death and OS as time from randomization to death. Prognostic factors analyzed were: treatment arm, age (≤80 vs >80), sex, rectum vs colon, primary tumor resected or not, doublet vs mono‐chemotherapy, body mass index (≥21 vs <21), Spitzer QoL (≤7 vs 8‐10), MNA‐SF (≥11 vs <11), G8 (>14 vs ≤14), ADL (6 vs <6), IADL (14 vs <14), mini‐COG ( positive vs negative), GDS (≥1 vs 0), presence of a caregiver, hospitalization in the 12 months previous randomization, energy testing (<5 vs ≥5), aging risk factor questionnaire (>2 vs ≤2), fall in the 6 months previous randomization or one‐leg balance, presence of anemia, albumin (>35 vs ≤35 g/L), creatinine clearance (>45 vs ≤45 mL/min), CEA (>2N vs ≤2N), CA19.9 (>2N vs ≤2N) and Köhne criteria (low vs intermediate vs high). Baseline variables significant at 15% in univariate analysis were introduced in the multivariate Cox model. Results: 102 pts were randomized (51 BEV‐CT, 51 CT) and 100 pts were treated: chemotherapy was LV5FU2 in 52 pts (26 BEV‐CT, 26 CT) and a doublet regimen in 48 pts (23 BEV‐CT, 25 CT) including 23 FOLFOX and 25 FOLFIRI. The median follow‐up was 20.4 months. 25 pts BEV‐CT and 31 pts CT received 2nde line chemotherapy. Multivariate analysis shows that Spitzer QoL, albumin and Köhne criteria were prognostic for OS. Spitzer QoL and Köhne criteria were also prognostic for PFS. (Table presented) Conclusions: Spitzer QoL and Köhne criteria are prognostic factors for OS and PFS and should be used as stratification factors in future trials in elderly pts. Pts with a prolonged OS were observed in BEV‐CT.
Cite
CITATION STYLE
Aparicio, T., Bouché, O., Francois, E., Maillard, E., Kirscher, S., Taieb, J., … Bedenne, L. (2016). Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20. Annals of Oncology, 27, vi194. https://doi.org/10.1093/annonc/mdw370.131
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.